CervoMed secures patent for neflamapimod
- CervoMed (NASDAQ:CRVO) has received a notice of allowance from the USPTO for a new patent protecting the use of neflamapimod to treat "pure" dementia with Lewy bodies (DLB).
- The patent provides intellectual property protection through 2042, with the potential for further extensions, supporting the company's focus on patients without Alzheimer’s-like tau pathology.
- Following the announcement, CervoMed shares were trading at approximately $4.72, reflecting a 23.88% increase.
CervoMed (NASDAQ:CRVO) announced on June 18, 2026, that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a new patent regarding its drug candidate, neflamapimod.
The patent covers the use of the oral small molecule to treat patients with dementia with Lewy bodies who lack substantial Alzheimer’s-like tau pathology—a population the company identifies as having "pure DLB."
By utilizing biomarkers such as plasma pTau levels or brain imaging to identify appropriate patients, the company aims to address a significant unmet need, as there are currently no treatments approved for DLB in the United States or the European Union.
The company previously reached alignment with the FDA in November 2025 on a potential registration path for the drug, though the initiation of a Phase 3 trial remains contingent on securing a partnership or additional financing.
Following the announcement, the CervoMed share price was $4.72.
CervoMed is a clinical-stage biotechnology company that focuses on developing treatments for age-related brain disorders by targeting neuroinflammation and neurodegeneration.
In addition to its DLB program, the company has recently completed enrollment in a Phase 2a clinical trial for neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA).
